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the study was conducted under the public health perspective, only direct medical
costs associated with the RSV treatment were evaluated (hospitalization, emer-
gency room, drugs, and prophylaxis). For resource utilisation purposes, an expert
panel of paediatricians with experience in RSV infection was convened. Drug and
medical attention costs were discounted by using a 3% discount rate and are re-
ported in local currency. Acceptability curves of the probability of palivizumab to
be cost effective were calculated. The threshold included in the study for cost-
effectiveness comparisons, is the proposed by the World Health Organisation (3
times the gross domestic product per capita). RESULTS: The ICER per QALY for the
study group was MXN $219,150. The acceptability curves showed a 75% probability
of palivizumab to be cost effective when employing a 3 times GDP threshold.
CONCLUSIONS: The use of palivizumab represents a cost-effective alternative for
the prophylaxis of complications associated with RSV infection, under the public
health perspective in Mexico for patients 29 WGA.
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COST-EFFECTIVENESS OF VARENICLINE VS EXISTING SMOKING CESSATION
STRATEGIES IN DOMINICAN REPUBLIC USING THE BENESCO MODEL
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OBJECTIVES: In Dominican Republic, the economic burden of tobacco has not been
assessed. The aim of this study was to evaluate the cost-effectiveness of vareni-
cline compared to other existing strategies for smoking cessation within a 5-year
time horizon in an adult population cohort from Dominican Republic using the
healthcare payer’s perspective. METHODS: The Benefits of Smoking Cessation on
Outcomes (BENESCO) simulation model was used for an adult cohort in Dominican
Republic (n6,528,125). Smoking cessation therapies compared were: varenicline
(0.5 – 2 mg/day) versus bupropion (300 mg/day); nicotine replacement treatment
(NRT) (5-10 mg/day) and unaided cessation. Effectiveness measures were: Life-Year
gained (LYG) and quality-adjusted life-year gained (QALY’s). Resource use and
costs data were obtained from Dominican Republic’s Ministry of Health and Social
Security databases (2009). The model used a 3% discount rate for costs (expressed
in 2009 US dollars) and health outcomes. Probabilistic sensitivity analyses (PSA)
were conducted and acceptability curves were constructed. RESULTS: Varenicline
reduced smoking-related morbidity, mortality and healthcare costs. After 5 years,
mortality in the varenicline arm was reduced by 67, 86 and 163 deaths compared
with bupropion, NRT and unaided cessation, respectively. The net average cost per
additional quitter showed that varenicline was cost-saving against competing al-
ternatives. Varenicline exhibited 145, 188 and 355 more QALYs against Bupropion,
NRT and unaided cessation, respectively. Cost-effectiveness analyses showed that
varenicline was the dominant strategy. At a willingness-to-pay of US$8,000/QALY,
the probability that varenicline is cost-effective met 100%. PSA results support the
robustness of the findings. CONCLUSIONS: Smoking cessation therapy with va-
renicline is cost-saving in Dominican Republic. These results could help to reduce
the tobacco related disease burden and align cost-containment policies.
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RHINITIS PATIENTS
Rely K1, Alexandre PK2, Anaya P3, Salinas GE4
1CEAHealthTech, México, D.F., México, 2Johns Hopkins University, Baltimore, MD, USA,
3GlaxoSmithKline México, México, D.F., México, 4Hospital Infantil de México Federico Gómez,
Secretaría de Salud, México, D.F., México
OBJECTIVES: To evaluate the cost-effectiveness of fluticasone furoate vs. mome-
tasone furoate in the treatment of ocular symptoms in allergic rhinitis patients in
Mexico. METHODS: A decision-analytic model was developed to estimate the cost-
effectiveness of fluticasone furoate versus mometasone furoate. Patients initiated
on treatment either completed initial therapy or switched to second line therapy
due to non-response. Probability of a switch and resource use was based on expert
panel and literature. Costs were based on local drug acquisition costs, local cost
estimates for outpatient and hospitalization. Effectiveness was defined as the net
improvement in Total Ocular Symptom Score (TOSS) at 12 weeks from Keith PK.
2009 study. The analysis was carried out from the perspective of the Mexican
health care system and all costs are reported in 2010 US dollars. RESULTS: The
corresponding health effects were 0.47 net improvement TOSS for fluticaone fu-
roate and 0.31 for mometasone furoate regimen. The mean total cost of the fluti-
caone furoate regimen was $ 627 compared with $ 827 for the furoate mometasone
regimen. Treatment with fluticasone furoate compared to treatment with mome-
tasone furoate was less costly and resulted in a greater net improvement of TOSS.
Probabilistic sensitivity analyses demonstrated that the cost savings observed
were maintained over a wide range of alternative values for costs and resource
utilization. CONCLUSIONS: Cost-effectiveness analysis indicated the dominance
of fluticasone furoate over mometasone furoate because of both lower costs and
greater efficacy. Cost savings with fluticasone furoate were attributable to lower
drug acquisition costs. In addition, a net improvement in ocular symptoms may be
expected in allergic rhinitis patients.
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OBJECTIVOS:Desarrollar un estudio de costo-efectividad que compare Ciclesonida
con Beclometasona en el control del asma. METODOLOGÍAS: Estudio Costo-Efec-
tividad, de cohortes, observacional, analítico, con información recolectada pro-
spectivamente, realizado desde la perspectiva institucional, incluyó pacientes
pediátricos con diagnóstico de asma no controlada admitidos durante Julio de 2010
los que recibieron Ciclesonida o Beclometasona como único medicamento contro-
lador. Se realizó seguimiento por 6 meses, basados en datos reportados por la
literatura se utilizó el porcentaje de pacientes libres de crisis asmáticas como vari-
able para el cálculo del tamaño muestral, la muestra necesaria fué de 20 pacientes
por cada alternativa, se incluyeron 94 pacientes con edades entre los 1 y 15 años, 47
recibieron Beclometasona y 47 Ciclesonida. La asignación fue de manera aleatoria.
La variable primaria de efectividad fue definida como el porcentaje de pacientes
libres de crisis durante el periodo de estudio, se definieron como variables genera-
doras de costo uso de medicamentos y estancia hospitalaria. Se calculó la razón
costo-efectividad incremental y se realizó un modelo mediante un árbol de
decisión. RESULTADOS: 17 pacientes estuvieron libres de crisis en el grupo de
Beclometasona, los costos de utilización de medicamentos en este grupo fueron de
$7255.564 pesos colombianos, los costos de hospitalización se calcularon en
$38,568.200, los costos totales ascendieron a $45,823.764 ($25,188.67 dólares). En el
grupo de Ciclesonida, 45 pacientes estuvieron libres de crisis, los costos por uti-
lización de medicamentos fueron de $14,982.172, los costos derivados de hospital-
ización se calcularon en $92,200, los costos totales alcanzaron los $15,074.372
($8291.73 dólares). La razón costo-efectividad incremental de Beclometasona ver-
sus Ciclesonida fue de -1’098.192. CONCLUSIONES: Al utilizar Ciclesonida el hos-
pital encuentra ahorros de $1098.192 pesos por cada paciente libre de crisis, desde
la perspectiva del hospital, el manejar un paciente con Beclometasona representa
un costo adicional de $1,098.192 que se podrían ahorrar si el paciente fuese mane-
jado con Ciclesonida.
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OBJECTIVES: To evaluate the economic benefits of an 8 week Ambulatory Pulmo-
nary Rehabilitation Program (PR) plus GOLD based standard treatment (ST) vs. ST
without PR of COPD patients after an acute exacerbation of the disease in the
Colombian Health Care System (CHCS). METHODS: Direct costs of ST and of PR
were calculated according to tertiary level university hospital’s registries during
one year and CHCS’s drugs prices; these costs and QALY were estimated for one
year by a Markov chain model based on Seymour’s study (Thorax, 2010) findings of
health care utilization and probability of death. Univariate sensitivity and proba-
bilistic analysis were performed by Monte Carlo method.RESULTS: Following acute
exacerbation of COPD the annual cost of PR plus ST was COL$ 4,594,407,00 (US$
2,483.46) vs. an annual cost of ST without PR of COL$ 9,124,326.00 (US$ 4,932.07).
QALY of PR plus ST patients: 0.86577; QALY of ST without PR: 0.852979. Mean
cost-effectiveness of PR plus ST: COL$5,306,729.00 (US$ 2,868.50) per QALY, cost-
effectiveness of ST without PR:$10,697,014.00 (US$ 5,782.17) per QALY. There was
absolute dominance of PR plus ST vs. ST without PR in all scenarios. In the sensi-
tivity analysis the absolute dominance is maintained for any cost of PR program
COL$ 5,302,428.00 (US$ 2.866,18). CONCLUSIONS: Global costs of Pulmonary Reha-
bilitation plus Standard Treatment are much lower than Standard Treatment with-
out Pulmonary Rehabilitation for patients after an acute exacerbation of COPD.
Pulmonary Rehabilitation is a highly cost-effective treatment for these patients in
the CHCS and probably in many other countries with similar socio-economic level,
specially of Latin America.
Respiratory-Related Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVOS: Estimar la máxima disponibilidad a pagar (DAP) por un tratamiento
efectivo de cesación tabáquica entre fumadores mexicanos e identificar los facto-
res sociodemográficos, de la historia de fumador y de su entorno asociados a esta
valoración. METODOLOGÍAS: Se realizó un estudio observacional de tipo transver-
sal. La muestra de análisis estuvo constituida por 777 fumadores que participaron
en la Encuesta Global de Tabaquismo en Adultos, México 2009. Se realizó un análi-
sis descriptivo y de asociación estadística que permitió caracterizar a los fuma-
dores y su DAP con base en variables socioeconómicas, demográficas, de su historia
de tabaquismo y de su entorno. RESULTADOS: El 74.4% de los fumadores eran del
sexo masculino, 51.4% consumía cigarrillos con una frecuencia diaria. Los fuma-
dores tenían más de 15 años fumando, 58.6% había realizado intentos previos de
cesación y alrededor del 10% conocía de la existencia de centros de ayuda para
dejar de fumar. En promedio, la DAP por un método efectivo de cesación fue $2573
pesos mexicanos. En los hombres, la DAP fue 2056 pesos menor que en las mujeres.
A mayor educación y mayor nivel socioeconómico (NSE), la DAP de los fumadores
aumentó en todos los modelos estimados. CONCLUSIONES: Las estimaciones del
presente estudio sugieren que los fumadores mexicanos que desean dejar de fu-
mar revelan, en términos monetarios, una alta valoración por un método de ce-
sación efectivo. Los fumadores del sexo masculino muestran un comportamiento
A566 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 5 3 5 - A 5 7 0
